Claims
- 1. A method of killing a targeted cell in vivo comprising the steps of (a) first administering to a targeted cell in vivo a vitamin D derivative and (b) subsequently administering to said cell a cytotoxic agent, wherein said cytotoxic agent is paclitaxel or cyclophosphamide.
- 2. The method of claim 1, wherein said cell is a neoplastic cell.
- 3. The method of claim 1, wherein said cell is within a tumor.
- 4. The method of claim 1, wherein said vitamin D derivative is 1,25D.sub.3.
- 5. The method of claim 1, wherein said vitamin D derivative is an analog of 1,25D.sub.3.
- 6. The method of claim 5, wherein said analog is a nonhypercalcemic analog.
- 7. The method of claim 5, wherein said analog is Ro23-7553 or Ro24-5531.
- 8. The method of claim 1, wherein said cytotoxic agent is paclitaxel.
- 9. The method of claim 1, wherein said cytotoxic agent is cyclophosphamide.
- 10. A method of retarding the growth of a tumor in vivo comprising the steps of (a) first administering to tumor in vivo a vitamin D derivative and (b) subsequently administering to said tumor a cyeotoxic agent, wherein said cytotoxic agent is paclitaxel or cyclophosphamide.
- 11. The method of claim 10, wherein said vitamin D derivative is 1,25D.sub.3.
- 12. The method of claim 10, wherein said vitamin D derivative is an analog of 1,25D.sub.3.
- 13. The method of claim 12, wherein said analog is a nonhypercalcemic analog.
- 14. The method of claim 12, wherein said analog is Ro23-7553 or Ro24-5531.
- 15. The method of claim 10, wherein said cytotoxic agent is paclitaxel.
- 16. The method of claim 10, wherein said cytotoxic agent is cyclophosphamide.
- 17. A method of killing a targeted cell comprising the steps of (a) first administering to a targeted cell a vitamin D derivative and (b) subsequently administering to said cell a cytotoxic agent, wherein said cytotoxic agent is paclitaxel or cyclophosphamide.
- 18. The method of claim 17, wherein said cell is a neoplastic cell.
- 19. The method of claim 17, wherein said cell is within a tumor.
- 20. The method of claim 17, wherein said vitamin D derivative is 1,25D3.
- 21. The method of claim 17, wherein said vitamin D derivative is an analog of 1,25D3.
- 22. The method of claim 21, wherein said analog is a nonhypercalcemic analog.
- 23. The method of claim 21, wherein said analog is Ro23-7553 or Ro24-5531.
- 24. The method of claim 17, wherein said cytotomic agent is paclitaxel.
- 25. The method of claim 17, wherein said cell is in vitro.
- 26. The method of claim 17, wherein said cytotoxic agent is cyclophosphamide.
- 27. A method of retarding the growth of a tumor comprising the steps of (a) first administering to a tumor a vitamin D derivative and (b) subsequently administering to said tumor a cytotoxic agent, wherein said cytotoxic agent is paclitaxel or cyclosphosphamide.
- 28. The method of claim 27, wherein said vitamin D derivative is 1,25D3.
- 29. The method of claim 27, wherein said vitamin D derivative is an analog of 1,25D3.
- 30. The method of claim 29, wherein said analog is a nonhypercalcemic analog.
- 31. The method of claim 29, wherein said analog is Ro23-7553 or Ro24-5531.
- 32. The method of claim 27, wherein said cytotoxic agent is paclitaxel.
- 33. The method of claim 27, wherein said tumor is in vitro.
- 34. The method of claim 27, wherein said cytotoxic agent is cyclophosphamide.
STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT
This invention was made with Government support under Grant Number RO1-CA67267 awarded by the National Cancer Institute of the National Institutes of Health. The United States Government may have certain rights in this invention.
US Referenced Citations (3)
Number |
Name |
Date |
Kind |
4973721 |
Ikekawa et al. |
Nov 1990 |
|
5763429 |
Bishop et al. |
Jun 1998 |
|
5795882 |
Bishop et al. |
Aug 1998 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
9300079 |
Jun 1992 |
WOX |